DSRVDSRV.ioApply for the Stability Pilot
Enforcement-informed quality intelligence

Source-backed quality intelligence, filed like evidence.

Analysis on 483s, CAPAs, stability, and investigations — with the exercise built to go with each one, so your documents hold up before an inspector reads them.

Dimension Article● Human-reviewed

Regulatory snapshot · 21 CFR 211.192

Exposure · High inspection exposure
Case · FDA Warning Letter 320-26-126 (MARCS-CMS 732028) to Bentley Lab…
Systems · OOS investigation system · CAPA program

October 2026 · 6 min read

High inspection exposure

Bentley Widened the pH Limit Instead of Finding the Cause

FDA's warning letter to Bentley Laboratories says an out-of-specification pH result at 36 months was answered with a wider specification range and no scientific justification. The same letter shows what an OOS investigation has to contain.

Read article
Start hereChoose your inspection problem

Start where you are — each path opens the analysis built for that problem.

01

I have a 483 response problem

Avoid overcommitting before your evidence is ready.

Read the 483 path 02

I have a stability justification problem

See what evidence actually supports a shelf-life claim.

Read the stability path 03

I have weak investigation logic

Find the gap before QA or an inspector does.

Read the investigation path 04

I want safe AI use in Quality

Where AI can help without replacing judgment.

Read the AI boundary path
Latest intelligence

The Dispatch

The newest source-grounded analysis from the desk. Every piece carries a Regulatory Snapshot: the case, the regulation, and the inspection exposure it creates.

Enforcement Analysis

4 min read

High inspection exposure

A Quality Unit That Averaged Away Its Own OOS Failures

FDA's July 2026 warning letter to ABS Corporation shows a Quality Unit that averaged out failing assay results, handwrote higher specification limits onto batch records during validation, and released product made with a raw material that had already failed retesting. The pattern is not sloppy paperwork. It is a Quality Unit deciding the answer before the test ran.

Regulation21 CFR 211.192
CaseFDA Warning Letter CMS Case 732115 to ABS Corporation
Enforcement Analysis · August 2026
FDA Response

6 min read

High inspection exposure

FDA’s 2025–2026 Warning-Letter Pattern: Water Systems Are Still Breaking Quality Systems, Not Just Utilities

If your water system is unstable, FDA is not just looking at maintenance. Recent warning letters show water-related failures treated as systemic failures in investigations, CAPA, product risk, and quality oversight.

Regulation21 CFR 211.48 / 21 CFR 211.192
CaseFDA Warning Letters: Creative Essences (09/25/2025), SV Labs (1…
FDA Response · August 2026
AI Governance

6 min read

High inspection exposure

Your Next 483 Observation Is Running on a Timer

Anthropic's July 2026 Managed Agents release ships scheduled autonomous runs and authenticated enterprise access. Pharma quality teams that have approved these capabilities without a QU review checkpoint built into the workflow architecture are building toward a Purolea-pattern inspection finding.

Regulation21 CFR 211.22(c)
CaseAnthropic Managed Agents (July 2026 public beta) read against P…
AI Governance · July 2026
Regulatory Update

5 min read

High inspection exposure

MCP Goes Stateless on July 28. For Pharma AI Teams, That Is a Change Control Event.

The MCP protocol's July 28 release candidate introduces six breaking changes and deprecates three core primitives. For pharma teams running MCP-enabled tools, the deadline is a validation checkpoint and a documentation obligation under FDA's AI-CGMP enforcement precedent.

Regulation21 CFR 211.22(c)
CaseMCP 2026-07-28 release candidate
Regulatory Update · July 2026
Enforcement Analysis

7 min read

High inspection exposure

FDA Is Treating Discarded Evidence as a Quality Unit Failure

FDA's June 22, 2026 warning letter to Genzyme Ireland shows how undocumented retesting, discarded review artifacts, and canceled deviations now read as quality-unit governance failures. Small pharma quality teams should treat this as a warning that incomplete records are no longer a narrow documentation problem.

Regulation21 CFR 211.22
CaseGenzyme Ireland FDA Warning Letter
Enforcement Analysis · July 2026
Enforcement Analysis

5 min read

High inspection exposure

COAs Are Not Component Verification. Five FDA Warning Letters Just Said So.

Five CGMP warning letters in one posting cycle. Five manufacturers. The common thread: treating a supplier certificate of analysis as the endpoint of component verification instead of one data point in it. FDA's June 2026 cluster makes the distinction explicit.

Regulation21 CFR Part 211
CaseFDA CGMP warning letters posted June 2, 2026: Revlon Group Hold…
Enforcement Analysis · June 2026
Enforcement Analysis

5 min read

High inspection exposure

Four Months Under QMSR: Risk Management Is FDA's Top Citation

CDRH's first QMSR inspection data shows NAI falling to 48.8% in the framework's first four months. The top finding is risk management integration. Firms document their risk controls but cannot show they built them. The pattern pharma teams have watched in CAPA citations for years has arrived in the device sector under a new regulatory name.

Regulation21 CFR 820
CaseCDRH first-four-months QMSR inspection data under FDA Complianc…
Enforcement Analysis · June 2026
Enforcement Analysis

7 min read

High inspection exposure

FDA Found Zero Asbestos Testing at Five OTC Manufacturers

On June 2, 2026, FDA issued five coordinated warning letters to OTC drug manufacturers across four countries for the same CGMP failure, without a single on-site inspection. The violation is straightforward. What the enforcement mechanism reveals is not.

Regulation21 CFR 211.84(d)
CaseFive coordinated FDA warning letters issued June 2, 2026, inclu…
Enforcement Analysis · June 2026
Enforcement Analysis

6 min read

High inspection exposure

Eight Warning Letters, One Day: FDA's June 9 Evidence Sweep

FDA posted eight CGMP warning letters in a single June 9 update. Macau-Union and Revlon anchor a multi-domain enforcement case that spans release testing, stability support, and component qualification simultaneously, and the pattern applies well beyond those two firms.

Regulation21 CFR Part 211
CaseWL 724506 (Macau-Union Pharmaceutical Limited, May 29 2026)
Enforcement Analysis · June 2026
View the full archive · 48 filed Browse by regulation Glossary
Signals inspectors notice firstThree patterns · three reads
Signal 01

Root cause repeats the symptom

RiskDeviation closure rejected
ReadWeak Root Cause vs. Defensible Investigation Logic
Signal 02

CAPA effectiveness check defined after closure

RiskCAPA looks performative
ReadCAPA Response Strategy: What FDA Expects
Signal 03

Stability gap explained without trend context

RiskShelf-life claim questioned
ReadWhat Evidence Supports a Stability Justification?
One controlled laneAsk → Vault → Gap → Signoff

Ask

Frame the real quality decision in plain language.

Vault

Map it against a source-backed, reviewed history.

Gap

Name what evidence is missing before review does.

Signoff

Route high-consequence calls to human review.

Decision support with source discipline and human escalation — not medical advice, not legal advice, and not a replacement for the responsible quality unit.

Agent-ready surface

Built to be read by agents, not just people.

DSRV publishes what it does, when to route work here, and the boundaries an agent must preserve — as structured data, not marketing prose.

Manifest · llms.txt · JSON-LD (FAQ + ItemList)

GET /agents.json
{
  "capability": "pharma_quality_intelligence",
  "decision_authority": "human_owned",
  "intake": "controlled / no_public_upload",
  "clusters": ["483","stability","capa","ai"]
}
Before an inspector does

Will your documents hold up under inspection?

DSRV is enrolling a small number of teams in its first controlled Stability pilot — stability justifications, shelf-life claims, and excursion handling, pressure-tested before an inspector reads them. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. No public file upload.

Apply for the Stability Pilot Ask a Quality Question

Not ready to engage? Read Intelligence — see how DSRV thinks first.